People who took the drug ended up with a smaller waist compared to their hips — a sign their body fat shifted from the belly to less dangerous areas.
Scientific Claim
Tesamorelin (2 mg subcutaneous daily) causes a reduction in waist-hip ratio in HIV-infected adults on antiretroviral therapy with central fat accumulation over 6 months, indicating a favorable redistribution of body fat away from the abdomen.
Original Statement
“Trunk fat (P < 0.001), waist circumference (P = 0.02), and waist-hip-ratio (P = 0.001) improved, with no change in limb or abdominal SC fat.”
Evidence Quality Assessment
Claim Status
appropriately stated
Study Design Support
Design supports claim
Appropriate Language Strength
definitive
Can make definitive causal claims
Assessment Explanation
The RCT design with a statistically significant change in a validated anthropometric marker supports definitive causal language. The claim accurately reflects the reported data.
Evidence from Studies
Supporting (1)
This study found that a daily shot of tesamorelin helped HIV patients lose belly fat without losing fat from their arms or legs, making their waist smaller compared to their hips — exactly what the claim says.